Because rivaroxaban, a direct oral anticoagulant (DOAC) targeting FXa, enhanced the infiltration of cytotoxic T cells (CTL) and dendritic cells (DC) to the tumor site [12], it has been proposed that targeting this pathway by oral FXa inhibitors (FXa-i) provides synergistic effects with ICI therapy. This evidence concerns the gene F10 and neoplasm.